查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046611

鴉片類藥物使用障礙治療市場：全球產業規模、佔有率、趨勢、機會和預測（按藥物類型、給藥途徑、分銷管道和地區分類）、競爭格局（2021-2031 年）

Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球鴉片類藥物使用障礙 (OUD) 治療市場預計將從 2025 年的 38.9 億美元穩步成長到 2031 年的 68.1 億美元，複合年成長率為 9.78%。

該市場涵蓋Buprenornhine、美沙酮和納曲酮等藥物製劑，這些藥物對於控制鴉片類藥物成癮至關重要，能夠緩解戒斷症狀並減少對藥物的渴望。市場成長的主要促進因素是鴉片類藥物成癮的激增，以及政府對輔助性治療（MAT）計畫的大幅增加。統計數據顯示，2011年至2026年間，職場藥物過量死亡人數增加了536%，凸顯了有效治療性介入的迫切需求。此外，結合行為療法和藥物療法的實證MAT模式的日益普及也顯著提升了市場需求，目前已有超過65萬人正在接受鴉片類藥物使用障礙（OUD）治療。預計到2024年，這將使美國每年的藥物過量死亡人數減少27%（暫定），凸顯了該市場在改善公眾健康方面發揮的關鍵作用。

市場概覽
預測期 2027-2031
市場規模（2025 年） 38.9億美元
市場規模（2031年） 68.1億美元
複合年成長率（2026-2031） 9.78%
快速成長的細分市場 促效劑
最大的市場 北美洲

市場促進因素

儘管取得了這些進展，但市場仍面臨許多挑戰。首要因素是根深蒂固的社會對成癮治療的污名化，阻礙了患者尋求必要的治療，也妨礙了公共衛生工作。此外，嚴格的管制藥品分銷法規結構給醫療服務提供者和藥房帶來了沉重的行政負擔，造成供應鏈瓶頸。這導致不同地區在獲得治療方面存在差異，到2025年，美國八分之一的地區將達到藥房短缺的標準，便印證了這一點。另一方面，一些關鍵趨勢正在積極地重塑市場。長效Buprenornhine注射的日益普及提高了治療的依從性和持續性，例如，Sublocade在2025年第三季的銷售額成長了15%，達到2.19億美元。同時，遠端醫療輔助性治療（MAT）服務的擴展，透過消除後勤障礙和減輕污名化，顯著提高了患者的治療可近性。像 Bicycle Health 這樣的公司已經成功資金籌措了1,650 萬美元，用於擴大其虛擬治療服務，目前已為超過 40,000 名患者提供該服務。

市場挑戰

儘管取得了這些進展，但市場仍面臨許多障礙。主要因素是社會上對成癮治療根深蒂固的污名化，阻礙了患者尋求必要的治療，也妨礙了公共衛生工作。此外，嚴格的管制藥品分銷法規結構給醫療服務提供者和藥房帶來了沉重的行政負擔，造成供應鏈瓶頸和治療取得方面的區域差異。到2025年，美國八分之一的地區將達到藥局短缺的標準，這便是明證。另一方面，一些關鍵趨勢正在積極地重塑市場。長效型Buprenornhine製劑的日益普及提高了治療的依從性和持續性，例如，Sublocade在2025年第三季的銷售額成長了15%，達到2.19億美元。同時，遠端醫療輔助性治療（MAT）服務的擴展透過消除後勤障礙和減少污名化，顯著提高了病患的就醫便利性。像 Bicycle Health 這樣的公司已經成功資金籌措了1,650 萬美元，用於擴大其虛擬治療服務，目前已為超過 40,000 名患者提供該服務。

市場趨勢

儘管有這些趨勢，市場仍面臨許多障礙。主要因素是根深蒂固的社會對成癮治療的污名化，這阻礙了患者尋求必要的治療，並妨礙了公共衛生工作。此外，嚴格的管制藥品分銷法規結構給醫療服務提供者和藥房帶來了沉重的行政負擔，造成供應鏈瓶頸和治療取得方面的區域差異。到2025年，美國八分之一的地區將符合藥局短缺的標準，這便是明證。另一方面，一些關鍵趨勢正在積極地重塑市場。長效Buprenornhine注射的日益普及提高了治療的依從性和連續性，例如，Sublocade在2025年第三季的銷售額成長了15%，達到2.19億美元。同時，遠距遠端醫療輔助性治療（MAT）服務的擴展透過消除物流障礙和減少污名化，顯著提高了病患的就醫便利性。例如，像 Bicycle Health 這樣的公司已經成功資金籌措了1,650 萬美元，用於擴大其虛擬治療服務，該服務目前已向超過 40,000 名患者提供。

目錄

第1章：引言

第2章 分析方法

第3章執行摘要

第4章：客戶心聲

第5章：全球鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
    • 以金額為準
  • 市佔率及預測
    • 依藥物類型（促效劑、拮抗劑、其他）
    • 給藥途徑（口服、注射、舌下、鼻腔）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲鴉片類藥物使用疾患治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 企業合併（M&A）
  • 產品發布
  • 近期趨勢

第13章：全球鴉片類藥物使用障礙治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Indivior PLC
  • Alkermes plc
  • Braeburn Pharmaceuticals, Inc.
  • Novartis AG
  • Purdue Pharma LP
  • Mallinckrodt Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Lundbeck A/S
  • Titan Pharmaceuticals, Inc.

第16章 策略建議

第17章 關於TSCI與免責聲明

簡介目錄
Product Code: 16779

The Global Opioid Use Disorder (OUD) Drugs Market is projected to expand robustly from USD 3.89 Billion in 2025 to USD 6.81 Billion by 2031, at a Compound Annual Growth Rate of 9.78%. This market encompasses pharmaceutical formulations like buprenorphine, methadone, and naltrexone, which are vital for managing opioid dependence by alleviating withdrawal symptoms and reducing cravings. Market growth is primarily driven by the escalating prevalence of opioid addiction, coupled with substantial increases in government funding dedicated to medication-assisted treatment (MAT) programs. The urgent need for effective therapeutic interventions is underscored by statistics showing a 536 percent rise in workplace overdose fatalities since 2011 by 2026. Moreover, the expanding adoption of evidence-based MAT models, combining behavioral therapy with pharmacotherapy, has significantly propelled demand, leading to over 650,000 individuals receiving OUD medications and contributing to a provisional 27 percent decrease in annual drug overdose deaths in the U.S. by 2024, emphasizing the market's critical role in public health improvement.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.89 Billion
Market Size 2031USD 6.81 Billion
CAGR 2026-20319.78%
Fastest Growing SegmentAgonist Drugs
Largest MarketNorth America

Market Driver

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Challenge

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Market Trends

Despite this progress, the market faces significant impediments, primarily from the persistent social stigma surrounding addiction treatment, which often discourages patients from seeking essential care and hinders public health initiatives. Furthermore, restrictive regulatory frameworks governing the distribution of controlled substances impose rigorous administrative burdens on healthcare providers and pharmacies, creating supply chain bottlenecks and resulting in geographic gaps in treatment availability, as evidenced by one in eight U.S. neighborhoods meeting pharmacy shortage criteria in 2025. Conversely, several key trends are actively reshaping the market: the rising adoption of long-acting injectable buprenorphine formulations is enhancing treatment adherence and continuity, exemplified by Sublocade's 15 percent revenue increase to $219 million in Q3 2025. Concurrently, the expansion of telehealth services for MAT delivery is critically widening patient access by removing logistical barriers and mitigating stigma, with companies like Bicycle Health securing $16.5 million in funding to scale virtual treatment services that have already reached over 40,000 patients.

Key Market Players

  • Indivior PLC
  • Alkermes plc
  • Braeburn Pharmaceuticals, Inc.
  • Novartis AG
  • Purdue Pharma L.P.
  • Mallinckrodt Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Lundbeck A/S
  • Titan Pharmaceuticals, Inc.

Report Scope

In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Opioid Use Disorder Drugs Market, By Drug Type

  • Agonist Drugs
  • Antagonist Drugs
  • Others

Opioid Use Disorder Drugs Market, By Route of Administration

  • Oral
  • Parenteral
  • Sublingual
  • Nasal

Opioid Use Disorder Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Opioid Use Disorder Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.

Available Customizations:

Global Opioid Use Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opioid Use Disorder Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
    • 5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Opioid Use Disorder Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Opioid Use Disorder Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Opioid Use Disorder Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Opioid Use Disorder Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Opioid Use Disorder Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Opioid Use Disorder Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Opioid Use Disorder Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Opioid Use Disorder Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Opioid Use Disorder Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Opioid Use Disorder Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Opioid Use Disorder Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Opioid Use Disorder Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Opioid Use Disorder Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Opioid Use Disorder Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Opioid Use Disorder Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Opioid Use Disorder Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Opioid Use Disorder Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Opioid Use Disorder Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Opioid Use Disorder Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Indivior PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Alkermes plc
  • 15.3. Braeburn Pharmaceuticals, Inc.
  • 15.4. Novartis AG
  • 15.5. Purdue Pharma L.P.
  • 15.6. Mallinckrodt Pharmaceuticals
  • 15.7. Johnson & Johnson Services, Inc.
  • 15.8. Pfizer Inc.
  • 15.9. Lundbeck A/S
  • 15.10. Titan Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer